Accelerated fraction radiotherapy with capecitabine as neoadjuvant therapy for borderline resectable pancreatic cancer.

CONCLUSIONS: Given the limited efficacy signal and severe gastric ulcerations, we do not recommend this regimen for pancreatic cancer. We also do not recommend the use of high doses per fraction outside a clinical trial. PMID: 24558510 [PubMed]

http://www.ncbi.nlm.nih.gov/pubmed/24558510?dopt=Abstract

Source: Gastrointestinal Cancer Research - June 4, 2015 Category: Cancer & Oncology Tags: Gastrointest Cancer Res Source Type: research